Physician profile
Barry D Brooks
NPI 1912949868
$12,456.02
in general payments reported to CMS, 2019-2025
21 companies · $71.17 in 2025
The $71.17 reported for 2025 was less than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $8,283 · 2020: $2,575 · 2021: $108 · 2022: $454 · 2023: $753 · 2024: $212 · 2025: $71.17.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,036.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,036.26 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genentech USA, INC. | $5,618.13 | 2019-2022 | |
| Verastem, INC. | $4,399.96 | 2019 | |
| Adaptive Biotechnologies Corporation | $750.00 | 2020 | |
| Merck Sharp & Dohme LLC | $231.67 | 2021-2023 | Keytruda, Welireg |
| Astrazeneca Pharmaceuticals LP | $189.33 | 2019-2022 | |
| E.R. Squibb & Sons, L.L.C. | $151.54 | 2019 | |
| Seagen INC. | $141.49 | 2022 | |
| Karyopharm Therapeutics INC. | $124.03 | 2020-2023 | Xpovio |
| Servier Pharmaceuticals LLC | $120.71 | 2023 | |
| Apellis Pharmaceuticals, INC. | $120.31 | 2023 | Empaveli |
| Genzyme Corporation | $119.16 | 2024 | |
| Cti Biopharma Corp. | $115.78 | 2023 | Vonjo |
| Mirati Therapeutics, INC. | $108.94 | 2023 | Krazati |
| Abbvie INC. | $97.70 | 2019-2025 | |
| Amgen INC. | $42.57 | 2024 | Lumakras |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $42.39 | 2023 | |
| Corcept Therapeutics | $37.93 | 2025 | Korlym |
| Sanofi-Aventis U.S. LLC | $20.50 | 2020 | |
| Pfizer INC. | $11.96 | 2019 | |
| Gilead Sciences, INC. | $11.92 | 2021 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Barry Brooks listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.